ImmuPharma (LON:IMM) Trading Down 11.5% – Should You Sell?

Shares of ImmuPharma plc (LON:IMM) fell 11.5% on Tuesday . The stock traded as low as GBX 3.50 ($0.05) and last traded at GBX 4.04 ($0.05). 45,036,766 shares traded hands during trading, an increase of 571% from the average session volume of 6,714,776 shares. The stock had previously closed at GBX 4.57 ($0.06).

ImmuPharma Price Performance

The company has a market cap of £16.82 million, a PE ratio of -673.33 and a beta of 1.53. The company’s 50 day simple moving average is GBX 2.06 and its two-hundred day simple moving average is GBX 2.67.

ImmuPharma (LON:IMM) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.